Probiotix Health PLC
F:X90
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
S
|
Suzhou YourBest New-type Materials Co Ltd
SZSE:301266
|
CN |
|
INKON Life Technology Co Ltd
SZSE:300143
|
CN |
Probiotix Health PLC
Non-Reccuring Items
Probiotix Health PLC
Non-Reccuring Items Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Non-Reccuring Items | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
P
|
Probiotix Health PLC
F:X90
|
Non-Reccuring Items
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Bicycle Therapeutics PLC
NASDAQ:BCYC
|
Non-Reccuring Items
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Immunocore Holdings PLC
NASDAQ:IMCR
|
Non-Reccuring Items
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Compass Pathways PLC
NASDAQ:CMPS
|
Non-Reccuring Items
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Genus PLC
LSE:GNS
|
Non-Reccuring Items
-£17.3m
|
CAGR 3-Years
7%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Oxford BioMedica PLC
LSE:OXB
|
Non-Reccuring Items
£9.9m
|
CAGR 3-Years
-23%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Probiotix Health PLC
Glance View
ProBiotix Health Plc develops probiotics (live microbes that, when ingested, can alter the composition of the microbiome and improve human health) to tackle cardiovascular disease and other lifestyle conditions which are affecting growing numbers of people across the world. The company is headquartered in York, North Yorkshire and currently employs 2 full-time employees. The company went IPO on 2022-03-31. The firm develops probiotics to tackle cardiovascular disease and other lifestyle conditions. The company manufactures cholesterol reducing probiotic, Lactobacillus plantarum ECGC13110402 (LP-LDL). ProBiotix commercializes LP-LDL as an ingredient and in a range of white and own-label products under its CholBiome range. The CholBiome portfolio consists of four products, namely CholBiome, CholBiome X3, CholBiome BP, and CholBiome VH. LP-LDL helps to improve blood lipid profiles and blood pressure. The firm's development pipeline is fuelled by its OptiScreen and OptiBiotic platform technologies designed to identify metabolic pathways and compounds that impact human physiology and bring potential health benefits. These platforms are applicable across a range of other human diseases. The firm is focused on identifying and developing microbial strains, compounds, and formulations for use in the nutraceutical industry.
